Clinical trial

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

NCT00919035

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-06-01

PhasePHASE2

Study timeline

Study start (unknown)2009-06-01Date precision: month

Registry last updated2014-06-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

toriselDRUG · verified · RxNorm: Torisel

Sponsors & collaborators

Oncology Specialists, S.C.lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00919035 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.